Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapyJoel D. Leverson, Andrew J. Souers, Michael J. Mitten et al.|Science Translational Medicine|2015Cited by 541
Navitoclax Enhances the Efficacy of Taxanes in Non–Small Cell Lung Cancer ModelsNguyen Tan, Lisa D. Belmont|Clinical Cancer Research|2011Cited by 102